Morphic Therapeutic

Oral integrin therapies for patients with immunological, fibrotic, neoplastic and vascular diseases. Morphic Tx is joining a three decade quest led by our scientific founder, Tim Springer, who initially discovered the integrin receptor family in the 1980s. This receptor family is an important drug target that has fueled the successful development of six injectable therapies approved for treatment of multiple sclerosis, ulcerative colitis, Crohn's disease, plaque psoriasis, acute coronary syndrome and complications during percutaneous coronary intervention. Despite blockbuster commercial success, integrins have remained out of reach as small molecule drugs...until now.

Website

http://www.morphictx.com

External link for Morphic Therapeutic

Industry

Pharmaceutical Manufacturing

Company size

51-200 employees

Headquarters

Waltham, MA

Type

Public Company

Founded

2015

Specialties

drug discovery and immunology